Variants of canine neoplastic histiocytic disease
| Disease type . | Histiocytoma . | LCH . | HS . | Hemophagocytic HS . |
|---|---|---|---|---|
| Cell of origin | LC | LC | iDC | Macrophage |
| Immunophenotype | CD1a, CD11c/CD18, IBA1, and E-cadherin | CD1a, CD11c/CD18, IBA1, and E-cadherin | CD1a, CD11c/CD18, and IBA1 | CD1a low and CD11d/CD18 |
| Typical biologic behavior | Benign | Variable; may spontaneously regress; systemic involvement associated with more aggressive disease | Aggressive | Highly aggressive |
| Recommended treatment | Active surveillance or resection in the absence of spontaneous regression | Active surveillance or consider CCNU in the absence of spontaneous regression | Surgery with or without radiotherapy with or without CCNU for localized HS; CCNU for disseminated or advanced disease | No consensus for effective treatment described |
| Disease type . | Histiocytoma . | LCH . | HS . | Hemophagocytic HS . |
|---|---|---|---|---|
| Cell of origin | LC | LC | iDC | Macrophage |
| Immunophenotype | CD1a, CD11c/CD18, IBA1, and E-cadherin | CD1a, CD11c/CD18, IBA1, and E-cadherin | CD1a, CD11c/CD18, and IBA1 | CD1a low and CD11d/CD18 |
| Typical biologic behavior | Benign | Variable; may spontaneously regress; systemic involvement associated with more aggressive disease | Aggressive | Highly aggressive |
| Recommended treatment | Active surveillance or resection in the absence of spontaneous regression | Active surveillance or consider CCNU in the absence of spontaneous regression | Surgery with or without radiotherapy with or without CCNU for localized HS; CCNU for disseminated or advanced disease | No consensus for effective treatment described |
HS, histiocytic sarcoma; iDC, interstitial dendritic cell.